Needham & Company LLC Reiterates “Buy” Rating for LivaNova (NASDAQ:LIVN)

Needham & Company LLC restated their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a $72.00 target price on the stock.

Several other equities analysts also recently issued reports on the stock. Barclays lifted their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a report on Monday, February 26th. StockNews.com raised LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Mizuho reaffirmed a buy rating and set a $75.00 price target on shares of LivaNova in a report on Wednesday, March 27th. Finally, Robert W. Baird boosted their price objective on LivaNova from $56.00 to $62.00 and gave the stock a neutral rating in a research note on Thursday, February 22nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, LivaNova presently has a consensus rating of Moderate Buy and a consensus price target of $66.20.

LivaNova Trading Up 2.0 %

LIVN stock opened at $64.15 on Wednesday. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.36. The company has a current ratio of 3.17, a quick ratio of 2.51 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $54.57 and its 200-day moving average is $50.94. The firm has a market cap of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.28. The firm had revenue of $294.90 million for the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The business’s revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 earnings per share. Equities analysts anticipate that LivaNova will post 3.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the business. Primecap Management Co. CA lifted its stake in shares of LivaNova by 7.3% during the third quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock valued at $305,930,000 after acquiring an additional 395,940 shares during the period. Vanguard Group Inc. increased its holdings in LivaNova by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock valued at $93,612,000 after purchasing an additional 100,133 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in LivaNova by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,241,985 shares of the company’s stock valued at $64,262,000 after purchasing an additional 74,067 shares during the last quarter. Greenlight Capital Inc. increased its holdings in LivaNova by 3.5% in the fourth quarter. Greenlight Capital Inc. now owns 1,229,316 shares of the company’s stock valued at $63,605,000 after purchasing an additional 42,040 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in LivaNova by 96.1% in the third quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after purchasing an additional 449,136 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.